Cessatech AS
8GN
Company Profile
Business description
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
Contact
Strandvejen 60
HellerupDK- 2900
DNKT: +45 93872309
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
Nvidia earns upgrade as AI buildouts accelerate
Demand for AI infrastructure shows no signs of slowing.
stocks
Weekly earnings wrap: FMG, WDS, COL and more
A closer look at the final major results from August reporting season.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,268.70 | 7.30 | 0.08% |
| CAC 40 | 8,319.87 | 142.52 | -1.68% |
| DAX 40 | 26,367.24 | 81.28 | 0.31% |
| Dow JONES (US) | 53,569.44 | 105.56 | 0.20% |
| FTSE 100 | 10,792.54 | 85.58 | -0.79% |
| HKSE | 25,690.52 | 124.78 | 0.49% |
| NASDAQ | 26,541.35 | 411.15 | 1.57% |
| Nikkei 225 | 66,555.99 | 424.02 | 0.64% |
| NZX 50 Index | 13,835.68 | 44.37 | -0.32% |
| S&P 500 | 7,730.99 | 55.29 | 0.72% |
| S&P/ASX 200 | 9,064.60 | 13.30 | 0.15% |
| SSE Composite Index | 3,959.64 | 3.07 | 0.08% |